Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11590088 | April, 2024 | Pending | Dermavant Sciences GmbH et al. | Encube Ethicals Pvt. Ltd. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11590088 | DERMAVANT SCI | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10335462 | March, 2024 | Pending | Novo Nordisk A/S | Apotex Inc. et al. |
US10335462 | November, 2023 | Trial Instituted | Novo Nordisk A/S | Sun Pharmaceutical Industries Ltd. et al. |
US10335462 | October, 2023 | Trial Instituted | Novo Nordisk A/S | DR. REDDY'S LABORATORIES, INC. et al. |
US10335462 | March, 2023 | Trial Instituted | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
US8129343 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
US8536122 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 1 month from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(8 years from now) | |
US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
New Indication(I-822) | Jan 16, 2023 |
New Dosing Schedule(D-185) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; An adjunct to diet and exercise to improve glycemic control in...
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11596600 | February, 2024 | Pending | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
US11833245 | January, 2024 | Trial Instituted | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
US8293742 | November, 2021 | Final Written Decision - Appealed | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
US9259425 | November, 2021 | Terminated-Settled | Eye Therapies, LLC | Slayback Pharma LLC |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(5 years from now) | |
US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(5 years from now) | |
US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(4 years from now) | |
US11833245 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11596600 | February, 2024 | Pending | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
US8293742 | November, 2021 | Final Written Decision - Appealed | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
US9259425 | November, 2021 | Terminated-Settled | Eye Therapies, LLC | Slayback Pharma LLC |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(4 years from now) | |
US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(5 years from now) | |
US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(5 years from now) |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11642370 | February, 2024 | Institution Denied | Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
US10653719 | September, 2020 | Institution Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
US10478453 | May, 2020 | Institution Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US11642370 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11642370 | February, 2024 | Institution Denied | Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
US10653719 | September, 2020 | Institution Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
US10478453 | May, 2020 | Institution Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US11642370 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) | |
US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(13 years from now) |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11672803 | November, 2023 | Trial Instituted | Pharmacyclics LLC | BeiGene USA, Inc. et al. |
US9795604 | March, 2019 | Final Written Decision | Pharmacyclics LLC et al. | Sandoz Inc. et al. |
US8754090 | April, 2015 | Terminated-Denied | Pharmacyclics, Inc. | Coalition for Affordable Drugs IV LLC |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-680) | Feb 12, 2017 |
New Indication(I-689) | Jul 28, 2017 |
New Indication(I-702) | Jan 29, 2018 |
New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
New Indication(I-729) | Mar 04, 2019 |
New Dosing Schedule(D-165) | May 06, 2019 |
New Indication(I-736) | May 06, 2019 |
New Indication(I-737) | May 06, 2019 |
New Indication(I-741) | Jan 18, 2020 |
New Indication(I-753) | Aug 02, 2020 |
Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
New Dosing Schedule(D-176) | Aug 24, 2021 |
M(M-236) | Jan 25, 2022 |
Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
ODE*(ODE*) | Aug 02, 2024 |
Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
M(M-14) | Aug 24, 2025 |
New Product(NP) | Aug 24, 2025 |
New Patient Population(NPP) | Aug 24, 2025 |
Pediatric Exclusivity(PED) | Feb 24, 2026 |
Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of mantle cell lymphoma; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more ...
Dosage: TABLET; CAPSULE; SUSPENSION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11311482 | June, 2023 | Institution Denied | Bausch Health Ireland Limited et al. | Padagis Israel Pharmaceuticals Ltd. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8129343 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
US8536122 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 1 month from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 20, 2022 |
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8129343 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
US8536122 | March, 2023 | Institution Denied | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 1 month from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
New Product(NP) | Jun 04, 2024 |
New Patient Population(NPP) | Dec 23, 2025 |
New Dosing Schedule(D-190) | Jul 21, 2026 |
New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: NA
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7713947 | October, 2022 | Trial Instituted | Merck Serono SA | TWi Pharmaceuticals, Inc. |
US8377903 | October, 2022 | Trial Instituted | Merck Serono SA | TWi Pharmaceuticals, Inc. |
US7713947 | January, 2023 | Trial Instituted | Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
US8377903 | January, 2023 | Trial Instituted | Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
US10849919 | February, 2023 | Terminated-Settled | Ares Trading SA | Hopewell Pharma Ventures, Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(1 year, 3 months from now) | |
US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(1 year, 8 months from now) | |
US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1....
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8846628 | February, 2023 | Terminated-Settled | CELGENE CORPORATION et al. | Apotex Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846628 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 01, 2023 |
Orphan Drug Exclusivity(ODE-320) | Sep 01, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10272083 | February, 2023 | Institution Denied | Acerta Pharma B.V. et al. | Sandoz Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
New Indication(I-817) | Nov 21, 2022 |
Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab
Dosage: CAPSULE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10272083 | February, 2023 | Institution Denied | Acerta Pharma B.V. et al. | Sandoz Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
New Indication(I-817) | Nov 21, 2022 |
Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11110087 | October, 2022 | Final Written Decision - Appealed | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US10993942 | February, 2022 | Final Written Decision - Appealed | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(8 years from now) | |
US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
New Indication(I-782) | Jun 08, 2021 |
M(M-228) | Jun 08, 2021 |
New Indication(I-789) | Nov 21, 2021 |
New Indication(I-795) | May 15, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
M(M-265) | Oct 16, 2023 |
Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatmen...
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7041786 | March, 2022 | Final Written Decision - Appealed | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
US7041786 | October, 2022 | Final Written Decision - Appealed | Bausch Health Ireland Limited et al. | MSN Laboratories Private Ltd. et al. |
US9610321 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
US9616097 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
US9919024 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
US9925231 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-764) | Jan 24, 2021 |
New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Chronic idiopathic constipation; Irritable bowel syndrome with constipation
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10828310 | February, 2022 | Final Written Decision - Appealed | Bayer Pharma AG et al. | Mylan Pharmaceuticals Inc. et al. |
US10828310 | September, 2022 | Final Written Decision | Bayer Pharma AG et al. | InvaGen Pharmaceuticals, Inc. et al. |
US10828310 | September, 2022 | Final Written Decision | Bayer Pharma AG et al. | Teva Pharmaceuticals USA, Inc |
US9539218 | May, 2018 | Terminated-Denied | Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc. |
US7157456 | October, 2016 | Terminated | Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc et al. |
US7585860 | October, 2016 | Terminated | Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
US7592339 | October, 2016 | Terminated | Bayer Intellectual Property GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
US9539218 | January, 2014 | Decision | Frank Misselwitz et al |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(5 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US7592339 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(13 years from now) | |
US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-643) | Nov 04, 2014 |
New Indication(I-660) | Nov 02, 2015 |
New Indication(I-661) | Nov 02, 2015 |
New Indication(I-662) | Nov 02, 2015 |
New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
New Dosing Schedule(D-168) | Oct 27, 2020 |
New Indication(I-824) | Oct 11, 2021 |
New Indication(I-810) | Oct 11, 2022 |
M(M-284) | Mar 10, 2023 |
New Indication(I-867) | Aug 23, 2024 |
New Product(NP) | Dec 20, 2024 |
Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Reduction of risk of myocardial infarction and ischemic stroke in p...
Dosage: TABLET; FOR SUSPENSION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-816) | May 02, 2022 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
New Indication(I-875) | Aug 25, 2024 |
New Indication(I-893) | May 25, 2025 |
Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
New Indication(I-924) | Oct 24, 2026 |
Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg)
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
New Product(NP) | Jan 25, 2017 |
New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
M(M-115) | Apr 06, 2015 |
M(M-176) | Apr 22, 2019 |
New Indication(I-750) | Aug 25, 2020 |
New Patient Population(NPP) | Jun 17, 2022 |
Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10286036 | February, 2022 | Terminated-Settled | Aurinia Pharmaceuticals Inc. | Sun Pharmaceutical Industries Ltd. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8642077 | November, 2021 | Terminated-Settled | Amarin Pharmaceuticals Ireland Limited | Hikma Pharmaceuticals USA Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 26, 2015 |
New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy
Dosage: CAPSULE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10596190 | October, 2021 | Final Written Decision | Oregon Health & Science University et al. | Hope Medical Enterprises, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 20, 2025 |
Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11458104 | October, 2021 | Decision | Mission Pharmacal Company |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458104 | MISSION PHARMACAL | Enteric coated tiopronin tablet |
Nov, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
ODE*(ODE*) | Jun 28, 2026 |
Drugs and Companies using TIOPRONIN ingredient
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10357567 | October, 2021 | Terminated | DUSA Pharmaceuticals, Inc. et al. | Biofrontera Inc. et al. |
US8216289 | August, 2018 | Terminated-Denied | DUSA Pharmaceuticals Inc. | Biofrontera Incorporated |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8216289 | SUN PHARM INDS INC | Illuminator for photodynamic therapy |
May, 2018
(6 years ago) | |
US10357567 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-82) | Mar 12, 2013 |
New Indication(I-766) | Mar 09, 2021 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-751) | Aug 30, 2020 |
New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
M(M-54) | Jun 24, 2024 |
Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US6890927 | June, 2021 | Terminated-Settled | Pfizer Inc. | Apotex Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(2 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-105) | Jul 22, 2014 |
M(M-143) | Oct 15, 2017 |
M(M-144) | Oct 15, 2017 |
M(M-183) | Aug 12, 2019 |
M(M-192) | Dec 16, 2019 |
M(M-237) | Feb 22, 2022 |
Pediatric Exclusivity(PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11324753 | February, 2021 | Decision | Supernus Pharmaceuticals, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Apr 29, 2025 |
New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10716793 | January, 2021 | Final Written Decision - Appealed | United Therapeutics Corporation | Liquidia Technologies, Inc. |
US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
US9339507 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
US9358240 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulinĀ® |
Dec, 2028
(3 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(3 years from now) | |
US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(3 years from now) | |
US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jul 30, 2012 |
Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
M(M-145) | May 20, 2017 |
New Indication(I-856) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10716793 | January, 2021 | Final Written Decision - Appealed | United Therapeutics Corporation | Liquidia Technologies, Inc. |
US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulinĀ® |
Dec, 2028
(3 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11458119 | November, 2020 | Decision | Hanlan Liu et al. | |
US10888547 | April, 2019 | Decision | Genzyme Corporation |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...
Dosage: CAPSULE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11389447 | October, 2020 | Decision | JANSSEN SCIENCES IRELAND UC |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-184) | Jan 31, 2025 |
New Patient Population(NPP) | Mar 29, 2025 |
New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US10596276 | October, 2020 | Institution Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
US10596278 | October, 2020 | Terminated-Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) | |
US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
New Patient Population(NPP) | Apr 23, 2027 |
Orphan Drug Exclusivity(ODE-479) | Apr 23, 2031 |
Pediatric Exclusivity(PED) | Oct 23, 2031 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 23 October, 2030
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8101659 | August, 2020 | Terminated-Denied | Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(25 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
New Patient Population(NPP) | Oct 01, 2022 |
Pediatric Exclusivity(PED) | Apr 01, 2023 |
M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8101659 | August, 2020 | Terminated-Denied | Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101659 | NOVARTIS | Methods of treatment and pharmaceutical composition |
Jan, 2025
(25 days ago) |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: NA
Dosage: CAPSULE, PELLETS
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11090280 | July, 2020 | Decision | PATHEON SOFTGELS INC | |
US9693978 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
US9693979 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9693979 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 21 days from now) | |
US9693978 | BIONPHARMA | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(1 year, 21 days from now) | |
US11090280 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 21 days from now) |
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary reduction of fever
Dosage: CAPSULE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 9 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
M(M-244) | Aug 12, 2022 |
M(M-187) | Dec 04, 2023 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
US6340475 | April, 2014 | Final Written Decision | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6635280 | April, 2014 | Final Written Decision | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6340475 | January, 2014 | FWD Entered | Depomed, Inc. | Purdue Pharma L.P. |
US6635280 | January, 2014 | FWD Entered | DepoMed, Inc. | Purdue Pharma L.P. |
US6340475 | April, 2014 | Institution Denied | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
US6635280 | April, 2014 | Institution Denied | Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 9 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6340475 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) | |
US6635280 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(8 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-244) | Aug 12, 2022 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
M(M-187) | Dec 04, 2023 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 9 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
M(M-244) | Aug 12, 2022 |
M(M-187) | Dec 04, 2023 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(1 year, 1 month from now) |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 18 September, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 9 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
M(M-275) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9815827 | June, 2020 | Final Written Decision | Sumitomo Dainippon Pharma Co., Ltd. et al. | Slayback Pharma LLC et al. |
US9555027 | April, 2017 | Terminated-Settled | Sumitomo Dainippon Pharma Co., Ltd. | Par Pharmaceutical, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(11 months ago) | |
US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(1 year, 3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-134) | Apr 26, 2015 |
New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
New Indication(I-674) | Jun 28, 2016 |
M(M-195) | Jan 27, 2020 |
Pediatric Exclusivity(PED) | Jul 27, 2020 |
New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia
Dosage: TABLET
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US11083730 | May, 2020 | Decision | Heron Therapeutics, Inc. | |
US11083797 | May, 2020 | Decision | Heron Therapeutics, Inc. | |
US10898575 | December, 2019 | Decision | Heron Therapeutics, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 12, 2024 |
New Indication(I-933) | Jan 23, 2027 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulinĀ® |
Dec, 2028
(3 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Dec 20, 2016 |
New Dosing Schedule(D-156) | Jan 28, 2019 |
New Dosing Schedule(D-157) | Jan 28, 2019 |
Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
New Indication(I-820) | Oct 18, 2022 |
Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulinĀ® |
Dec, 2028
(3 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in RemodulinĀ® |
Dec, 2028
(3 years from now) |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: NA
Dosage: INJECTABLE; SOLUTION
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9439906 | February, 2020 | Terminated-Denied | Janssen Pharmaceutica NV | Mylan Laboratories Ltd. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
New Dosage Form(NDF) | Jul 31, 2012 |
Pediatric Exclusivity(PED) | Jan 31, 2013 |
M(M-119) | Aug 29, 2015 |
New Indication(I-698) | Nov 12, 2017 |
M(M-215) | Dec 20, 2020 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US8163723 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
US8168620 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
US9259428 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
US9901585 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
US8168620 | February, 2017 | Terminated-Settled | Cipla Limited | Argentum Pharmaceuticals LLC |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(1 year, 7 months ago) | |
US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(1 year, 5 months ago) | |
US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(1 year, 7 months ago) | |
US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(1 year, 14 days from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | May 01, 2015 |
New Patient Population(NPP) | Feb 20, 2018 |
Pediatric Exclusivity(PED) | Aug 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis
Dosage: SPRAY, METERED
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9533053 | December, 2019 | Terminated-Denied | Novartis AG | AYLA PHARMA LLC |
US8791154 | June, 2018 | Terminated-Settled | Alcon Research Ltd. | Cipla Limited |
US9533053 | June, 2018 | Terminated-Settled | Alcon Research Ltd. | Cipla Limited |
US8791154 | February, 2016 | Terminated-Settled | Alcon Research, Ltd. | Argentum Pharmaceuticals, LLC |
US8791154 | August, 2016 | Terminated-Settled | Alcon Research, Ltd. | Apotex, Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(7 years from now) | |
US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 30, 2018 |
Pediatric Exclusivity(PED) | Jul 30, 2018 |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
![]() | ||||
US9138456 | November, 2019 | Terminated-Denied | Cubist Pharmaceuticals LLC | Amneal Pharmaceuticals LLC |
US8058238 | July, 2015 | Terminated-Settled | Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
US8129342 | July, 2015 | Terminated-Settled | Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
US6468967 | November, 2014 | FWD Entered | Cubist Pharmaceuticals LLC | Fresenius-Kabi USA LLC |
US6852689 | November, 2014 | FWD Entered | Cubist Pharmaceuticals LLC | Fresenius-Kabi USA LLC |
US8058238 | July, 2015 | Terminated-Denied | Cubist Pharmaceuticals LLC | Fresenius Kabi USA LLC |
US6468967 | October, 2014 | Terminated-Denied | Cubist Pharmaceuticals, Inc. | Agila Specialties Inc. |
US6852689 | October, 2014 | Terminated-Denied | Cubist Pharmaceuticals Incorporated | Agila Specialties Inc. |
US8058238 | October, 2014 | Terminated-Denied | Cubist Pharmaceuticals, Inc. | Agila Specialities Inc. |
US8058238 | October, 2014 | Terminated-Denied | Cubist Pharmaceuticals, Inc. | Agila Specialties Inc. |
US8129342 | October, 2014 | Terminated-Denied | Cubist Pharmaceuticals, Inc. | Agila Specialities Inc. |
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(5 years from now) | |
US6468967 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(5 years ago) | |
US8058238 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(4 years ago) | |
US6852689 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(5 years ago) | |
US8129342 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Mar 29, 2020 |
M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: Method of treating bacterial infections
Dosage: POWDER